Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05382286 |
|---|---|
| Brief Title: | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) |
| First Submitted : | May 16, 2022 |
| First Submitted that Met QC Criteria : | May 16, 2022 |
| First Posted : | May 19, 2022 |
| Last Update Submitted that Met QC Criteria : | May 8, 2024 |
| Last Update Posted : | May 9, 2024 |